Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on Repare Therapeutics (RPTX – Research Report). The associated price target is $25.00.
Robert Burns has given his Buy rating to Repare Therapeutics based on several key factors. Firstly, the company recently unveiled preclinical data for two of its assets, RP-1664 (a PLK4 inhibitor) and RP-3467 (a DNA Polθ inhibitor). Notably, the PLK4 inhibitor, RP-1664, shows promising results in treating TRIM37-amplified tumors. This is significant as PLK4 inhibition was recently identified as synthetic lethal in these types of tumors, meaning it targets cancer cells without affecting healthy ones. RP-1664 demonstrated a high level of selectivity for PLK4, with minimal impact on Aurora A and Aurora B kinases, which are often associated with adverse side effects.
Moreover, preclinical models reveal that RP-1664 achieved robust and dose-dependent activity in multiple TRIM37-high models across a variety of tumor types, including breast cancer, non-small cell lung cancer (NSCLC), and neuroblastoma. This indicates its potential to address a large population and meet an unmet need in up to 63,000 patients across tumor types. Repare Therapeutics plans to initiate a Phase 1/2 trial to evaluate RP-1664 across a variety of TRIM37-high solid tumor types, further demonstrating their confidence in this therapy. These factors combined seem to indicate a promising future for Repare Therapeutics, leading to the Buy rating from Robert Burns.
Burns covers the Healthcare sector, focusing on stocks such as BioNTech SE, Exelixis, and Kineta. According to TipRanks, Burns has an average return of -38.8% and a 14.00% success rate on recommended stocks.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Repare Therapeutics (RPTX) Company Description:
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Read More on RPTX:
- Repare to advance RP-1664 and RP-3467 into Phase 1 clinical trials in 2024
- Repare Therapeutics reports Q3 EPS (45c), consensus (86c)
- Repare Therapeutics price target lowered to $25 from $30 at Piper Sandler
- Repare Therapeutics combo efficacy data looks ‘encouraging,’ says Stifel
- Repare Therapeutics announces data from Phase 1 MYTHIC clinical trial
